Experimental MS drug tested in kids, but study halted early
NCT ID NCT03368664
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested the drug alemtuzumab in children aged 10 to 18 with relapsing-remitting multiple sclerosis (MS) whose disease was still active despite other treatments. The goal was to see if the drug could reduce new brain lesions and improve quality of life. However, the trial was terminated early after enrolling only 16 participants, so the findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Alemtuzumab (also known as Lemtrada)
What this could lead to
If successful, this could provide a treatment option for children with active MS who have not responded to other therapies.
What could go wrong
The trial was terminated early with only 16 participants, so results are limited. Alemtuzumab also carries risks of serious autoimmune reactions and infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING - REMITTING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 0400001
Vienna, 1090, Austria
-
Investigational Site Number : 2500001
Le Kremlin-Bicêtre, 94270, France
-
Investigational Site Number : 2500002
Strasbourg, 67091, France
-
Investigational Site Number : 3800001
Milan, 20132, Italy
-
Investigational Site Number : 3800004
Naples, Napoli, 80131, Italy
-
Investigational Site Number : 3800005
Cagliari, 09126, Italy
-
Investigational Site Number : 6160001
Warsaw, 04-730, Poland
-
Investigational Site Number : 6160002
Poznan, Greater Poland Voivodeship, 60-355, Poland
-
Investigational Site Number : 6160003
Lodz, Lódzkie, 93-338, Poland
-
Investigational Site Number : 6430001
Moscow, 119602, Russia
-
Investigational Site Number : 6430002
Saint Petersburg, 197110, Russia
-
Investigational Site Number : 6430004
Moscow, 129110, Russia
-
Investigational Site Number : 6430005
Saint Petersburg, 197022, Russia
-
Investigational Site Number : 7920001
Ankara, 06500, Turkey (Türkiye)
-
Investigational Site Number : 7920003
Istanbul, 34390, Turkey (Türkiye)
-
Investigational Site Number : 8260002
London, London, City of, WC1N 3JH, United Kingdom